FHI Clinical goes where our expertise is needed. Whether it requires working from a state-of-the-art facility or in a low-tech, rural setting, we provide services tailored to meet your study needs, from protocol design and site assessments to trial planning, implementation and management.
We offer a unique combination of in-country technical, regulatory and cultural knowledge and an established global presence in Africa, Asia, Europe, Latin America and North America.
We adapt our processes and workflow as your study needs change. No matter how large or small the project, we remain agile and exact, because your research demands it.
We have research at our core. A subsidiary of FHI 360, we benefit from our parent company’s 40+ year history of clinical research and success in creating and growing CROs.
Our mission is to address unmet research needs and achieve maximum social impact by supporting the development of life-saving vaccines and medicines.
Let us help you enter hard-to-reach markets and access the right patient populations.
Tailored services to meet your needs, from protocol design and site assessments to trial planning, implementation and management.
Ability to address challenges across dozens of therapeutic areas , including infectious diseases (IDs), oncology, neglected tropical diseases (NTDs), emerging and reemerging diseases, and pediatric studies.
Leverage established partnerships with leading public and private medical research organizations, pharmaceutical and biotechnology companies, academic institutions, the U.S. National Institutes of Health (NIH), the U.S. Centers for Disease Control and Prevention (CDC) and the U.S. Agency for International Development (USAID).
April 9, 2019
FHI Clinical, Inc. announces its launch today as a full-service contract research organization (CRO) with the global expertise, responsive approaches and proven solutions to manage complex clinical research in resource-limited settings around the world.
November 20-24, 2019
We hope to see you at the ASTMH 2019 Annual Meeting. Visit us at the FHI Clinical booth to learn more about our support during the 2015 – 2018 Chikungunya vaccine phase II trial.
The Democratic Republic of Congo (DRC) is currently experiencing the world’s second-largest Ebola outbreak. Despite a coordinated vaccination and containment effort that began in August 2018, cases continue to occur and spread. As with other disease outbreaks in limited-resource countries, numerous factors have challenged the Ebola health care response in the DRC.
